Biogen Gets FDA Approval for Leqembi Iqlik as Initiation Dose for Early Alzheimer's Disease
() -- Biogen (BIIB) and Eisai said late Monday that the US Food and Drug Administration has approved a supplemental biologics license application for Leqembi Iqlik, a once-weekly subcutaneous injection, as an initiation dose for the treatment of early Alzheimer's disease. Leqembi Iqlik is administered via an auto-injec